At a glance
ClinicalIndex Comparison Record- ✓Heart rate greater than 125 bpm
- ✓Systolic blood pressure greater than 110 mmHg
- ✓Atrial fibrillation or atrial flutter confirmed on ECG
- ✓Ability to perform activities of daily living (meets observation unit requirements)
- ✕Wolf-Parkinson-White syndrome
- ✕ST elevation myocardial infarction
- ✕Pregnancy
- ✕Clinical diagnosis of sepsis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Emergency Department Atrial Fibrillation Oral Diltiazem Observation Protocol
In Brief
A Phase 4 clinical trial evaluating Oral and Intravenous drug for Atrial Fibrillation and Atrial Flutter. Completed, enrolled 444 participants across 1 site.
Detailed Summary
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.
Study Details
Timeline
Interventions
Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.